Human Recombinant Insulin Market Overview

Human recombinant insulin is the synthetic insulin, resulted utilizing recombinant DNA technology. The Global Human Recombinant Insulin Market is growing at significant rate, due to mounting occurrence diabetes and mounting need for human insulin analogs. Different product type contributed to the human recombinant insulin market size. The market has witnessed high demand for long acting human insulin in the coming years due to advanced competence and capability to pose constant insulin delivery during the day.

Market Segmentation

Insight by Product Type

The various types of products offered in the market are rapid-acting, long-acting, short-acting, premixed, and intermediate-acting. Of all product type, long-acting human insulin segment is expected to grow at the fastest rate in the market due to advanced competence and capability to pose constant insulin delivery during the day.

Insight by Brand

On the basis of brand, the market is subdivided into Humalog, Lantus, Novolog, Novorapid, Apidra, Humulin, Novolin, Levemir and others. Of all the brands, the Lantus accounted the foremost share in the human recombinant insulin market. In addition, Levemir and Apidra are expected to grow at fastest rate in the market.

Insight by Distribution Channel

On the basis of distribution channel, the market is subdivided into hospital pharmacies, online pharmacies and retail pharmacies. Among the all distribution channels, the retail pharmacies accounted the largest share in the human recombinant insulin market, as it offers extensive range of diabetic products including over-the-counter and prescription drugs for the diabetic patients.

Insight by Application

On the basis of application, the market is subdivided into type I diabetes and type II diabetes. Type I diabetes accounts for about 5 to 10 percent of the diabetes cases and type II accounts for approximately 90 percent of the diabetic cases. Many patients with type II diabetes are asymptomatic. Among the both applications, the type II diabetes accounted the largest share in the human recombinant insulin market due to mounting incidence of type II diabetes. For instance, according to International Diabetes Federation (IDF) in 2017, globally approximately 352 million people were at risk of developing type II diabetes.

Industry Dynamics

Growth Drivers

Mounting number of diabetic patients, promising medical reimbursement setup in developed countries, escalating risk factors leading to diabetes, intensifying market availability of generic human insulin products and mounting need for human insulin analogs are the primary growth drivers for human recombinant insulin market. For instance, according to World Health Organization (WHO), globally the number of people with diabetes has risen from 108 million in 1980 to 422 million in 2014. In addition, according to IDF in 2017, globally approximately 425 million adults were suffering from diabetes and are expected to reach 629 million in 2045.

Expected patent expiry of major human analog drugs, expanding geriatric population, mounting R&D for drug discovery & development and technological advancement in human insulin delivery devices are also facilitating the growth for the human recombinant insulin market.

Mounting government schemes to support the expansion and commercialization of efficient biosimilars are also driving the growth of the market. For instance, several government and private research organizations are involved in R&D activities for evolving innovative treatment in diabetes care to upsurge the efficacy of human insulin, decrease diabetes affliction, and diminish the threat of diabetes related disorders.

Challenges

Elevated product manufacturing cost and strict regulatory requirement for the sanction of the products are the major challenges for the growth of human recombinant insulin market.

Industry Ecosystem

Globally, the manufacturing companies trying to enter the human recombinant insulin market are required to maintain stringent regulatory standards. Moreover, the high level of capital requirement also poses a major barrier for the entry of new players. This offers an edge to the established players in the industry competition.

Geographic Overview

Geographically, North America is the largest human recombinant insulin market as in the region the number of diabetic patients is increasing. For instance, according to Centers for Disease Control and Prevention (CDC), in 2015 approximately 23.1 million people in the U.S. had diabetes. Expanding geriatric population and technological advancement in the insulin delivery devices are also up surging growth of the North American human recombinant insulin market.

Asia-Pacific is observed to witness fastest growth in the market, due to mounting number of diabetic patients. In addition, mounting healthcare expenditure, developing regulatory skeleton for promoting approvals & medical repayments, reinforcing distribution networks of product manufacturers and expanding awareness about diabetes are also creating a positive impact on the human recombinant insulin market growth in the region.

Competitive Insight

Novo Nordisk is a leading global healthcare company headquartered in Denmark. Company help to defeat serious chronic diseases which is done by pioneering scientific breakthroughs, expanding access to the medicines, and working to prevent and ultimately cure disease.

Biocon is a global biopharmaceutical company which is into the treatment of diabetes, cancer and autoimmune diseases and believes that everyone has a right to affordable quality medicines. Company's R&D focuses on prevention, alleviation and treatment and medicines to improve the lives of millions of patients accross the world by giving them access to life-saving therapies and relief.

Key players in the human recombinant insulin market are catering the demand of these devices by investing on technologically advanced products in their product portfolio across the globe.

Novo Nordisk A/S, Biocon Limited, Sanofi S.A., Wanbang Biopharmaceuticals Co., Ltd., Bioton S.A., Eli Lilly and Company, Zhuhai United Laboratories Co., Ltd., Julphar Gulf Pharmaceutical Industries, Dongbao Enterprise Group Co., Ltd, and Gan & Lee Pharmaceuticals, Ltd. are the key players offering human recombinant insulin products.

Recent Developments by Key Players

Biocon Limited is an innovation-led global biopharmaceutical company has signed an exclusive licensing and supply agreement with Handok, a specialty pharmaceutical company in South Korea, for the commercialization of its vertically integrated, complex drug product.

Novo Nordisk A/S has acquired Cardior Pharmaceuticals for up to USD 1 billion as the Danish maker of weight-loss drugs continues to expand into treatments for cardiovascular disease.

The Human Recombinant Insulin Market report offers a comprehensive market segmentation analysis along with an estimation for the forecast period 2026–2035.

Segments Covered in the Report

• By Product Type
  • Rapid-Acting
  • Long-Acting
  • Short-Acting
  • Premixed
  • Intermediate-Acting
• By Brand
  • Humalog
  • Lantus
  • Novolog
  • Novorapid
  • Apidra
  • Humulin
  • Novolin
  • Levemir
  • Others
• By Distribution Channel
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
• By Application
  • Type I
  • Type II

Region Covered in the Report

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia-Pacific (APAC)
  • China
  • Japan
  • India
  • South Korea
  • Rest of Asia-Pacific
• Rest of the World (RoW)
  • Brazil
  • Saudi Arabia
  • South Africa
  • U.A.E.
  • Other Countries

Source: VynZ Research

Source: VynZ Research

Table of Contents for Human Recombinant Insulin Market Report

1.    Research Overview

        1.1.    The Report Offers
        1.2.    Market Coverage
                  1.2.1.    By Product Type 
                  1.2.2.    By Brand 
                  1.2.3.    By Distribution Channel 
                  1.2.4.    By Application 
        1.3.    Research Phases
        1.4.    Limitations
        1.5.    Market Methodology
                  1.5.1.  Data Sources
                             1.5.1.1. Primary Research
                             1.5.1.2. Secondary Research
                  1.5.2.  Methodology
                             1.5.2.1. Data Exploration
                             1.5.2.2. Forecast Parameters
                             1.5.2.3. Data Validation
                             1.5.2.4. Assumptions
                  1.5.3.  Study Period & Data Reporting Unit

2.    Executive Summary

3.    Industry Overview

       3.1.    Industry Dynamics
                 3.1.1.    Market Growth Drivers
                 3.1.2.    Market Restraints
                 3.1.3.    Key Market Trends
                 3.1.4.    Major Opportunities
       3.2.    Industry Ecosystem
                 3.2.1.    Porter’s Five Forces Analysis
                 3.2.2.    Recent Development Analysis
                 3.2.3.    Value Chain Analysis
       3.3.    Competitive Insight
                 3.3.1.    Competitive Position of Industry Players
                 3.3.2.    Market Attractive Analysis
                 3.3.3.    Market Share Analysis

4.    Global Market Estimate and Forecast

       4.1.    Global Market Overview
       4.2.    Global Market Estimate and Forecast to 2035

5.    Market Segmentation Estimate and Forecast

       5.1.    By Product Type 
                 5.1.1. rapid-acting
                           5.1.1.1. Market Definition
                           5.1.1.2. Market Estimation and Forecast to 2035
                 5.1.2. long-acting
                           5.1.2.1. Market Definition
                           5.1.2.2. Market Estimation and Forecast to 2035
                 5.1.3. short-acting
                           5.1.3.1. Market Definition
                           5.1.3.2. Market Estimation and Forecast to 2035
                 5.1.4. premixed
                           5.1.4.1. Market Definition
                           5.1.4.2. Market Estimation and Forecast to 2035
                 5.1.5. intermediate-acting
                           5.1.5.1. Market Definition
                           5.1.5.2. Market Estimation and Forecast to 2035

       5.2.    By Brand 
                 5.2.1. Humalog
                           5.2.1.1. Market Definition
                           5.2.1.2. Market Estimation and Forecast to 2035
                 5.2.2. Lantus
                           5.2.2.1. Market Definition
                           5.2.2.2. Market Estimation and Forecast to 2035
                 5.2.3. Novolog
                           5.2.3.1. Market Definition
                           5.2.3.2. Market Estimation and Forecast to 2035
                 5.2.4. Novorapid
                           5.2.4.1. Market Definition
                           5.2.4.2. Market Estimation and Forecast to 2035
                 5.2.5. Apidra
                           5.2.5.1. Market Definition
                           5.2.5.2. Market Estimation and Forecast to 2035
                 5.2.6. Humulin
                           5.2.6.1. Market Definition
                           5.2.6.2. Market Estimation and Forecast to 2035
                 5.2.7. Novolin
                           5.2.7.1. Market Definition
                           5.2.7.2. Market Estimation and Forecast to 2035
                 5.2.8. Levemir
                           5.2.8.1. Market Definition
                           5.2.8.2. Market Estimation and Forecast to 2035
                 5.2.9. others
                           5.2.9.1. Market Definition
                           5.2.9.2. Market Estimation and Forecast to 2035

       5.3.    By Distribution Channel 
                 5.3.1. hospital pharmacies
                           5.3.1.1. Market Definition
                           5.3.1.2. Market Estimation and Forecast to 2035
                 5.3.2. online pharmacies
                           5.3.2.1. Market Definition
                           5.3.2.2. Market Estimation and Forecast to 2035
                 5.3.3. retail pharmacies
                           5.3.3.1. Market Definition
                           5.3.3.2. Market Estimation and Forecast to 2035

       5.4.    By Application 
                 5.4.1. type I diabetes
                           5.4.1.1. Market Definition
                           5.4.1.2. Market Estimation and Forecast to 2035
                 5.4.2. type II diabetes
                           5.4.2.1. Market Definition
                           5.4.2.2. Market Estimation and Forecast to 2035

6.   North America Market Estimate and Forecast

      6.1.    By Product Type   
      6.2.    By Brand   
      6.3.    By Distribution Channel   
      6.4.    By Application   
                6.4.1.     U.S. Market Estimate and Forecast
                6.4.2.     Canada Market Estimate and Forecast
                6.4.3.     Mexico Market Estimate and Forecast

7.   Europe Market Estimate and Forecast

      7.1.    By Product Type   
      7.2.    By Brand   
      7.3.    By Distribution Channel   
      7.4.    By Application   
                7.4.1.     Germany Market Estimate and Forecast
                7.4.2.     France Market Estimate and Forecast
                7.4.3.     U.K. Market Estimate and Forecast
                7.4.4.     Italy Market Estimate and Forecast
                7.4.5.     Spain Market Estimate and Forecast
                7.4.6.     Russia Market Estimate and Forecast
                7.4.7.     Rest of Europe Market Estimate and Forecast

8.   Asia-Pacific (APAC) Market Estimate and Forecast

      8.1.    By Product Type   
      8.2.    By Brand   
      8.3.    By Distribution Channel   
      8.4.    By Application   
                8.4.1.     China Market Estimate and Forecast
                8.4.2.     Japan Market Estimate and Forecast
                8.4.3.     India Market Estimate and Forecast
                8.4.4.     South Korea Market Estimate and Forecast
                8.4.5.     Rest of Asia-Pacific Market Estimate and Forecast

9.   Rest of the World (RoW) Market Estimate and Forecast

      9.1.    By Product Type   
      9.2.    By Brand   
      9.3.    By Distribution Channel   
      9.4.    By Application   
                9.4.1.     Brazil Market Estimate and Forecast
                9.4.2.     Saudi Arabia Market Estimate and Forecast
                9.4.3.     South Africa Market Estimate and Forecast
                9.4.4.     U.A.E. Market Estimate and Forecast
                9.4.5.     Other Countries Market Estimate and Forecast

10.  Company Profiles

       10.1.   Novo Nordisk A/S
                  10.1.1.    Snapshot
                  10.1.2.    Overview
                  10.1.3.    Offerings
                  10.1.4.    Financial Insight
                  10.1.5.    Recent Developments
       10.2.   Biocon Limited
                  10.2.1.    Snapshot
                  10.2.2.    Overview
                  10.2.3.    Offerings
                  10.2.4.    Financial Insight
                  10.2.5.    Recent Developments
       10.3.   Sanofi S.A.
                  10.3.1.    Snapshot
                  10.3.2.    Overview
                  10.3.3.    Offerings
                  10.3.4.    Financial Insight
                  10.3.5.    Recent Developments
       10.4.   Wanbang Biopharmaceuticals Co. Ltd.
                  10.4.1.    Snapshot
                  10.4.2.    Overview
                  10.4.3.    Offerings
                  10.4.4.    Financial Insight
                  10.4.5.    Recent Developments
       10.5.   Bioton S.A.
                  10.5.1.    Snapshot
                  10.5.2.    Overview
                  10.5.3.    Offerings
                  10.5.4.    Financial Insight
                  10.5.5.    Recent Developments
       10.6.   Eli Lilly and Company
                  10.6.1.    Snapshot
                  10.6.2.    Overview
                  10.6.3.    Offerings
                  10.6.4.    Financial Insight
                  10.6.5.    Recent Developments
       10.7.   Zhuhai United Laboratories Co. Ltd.
                  10.7.1.    Snapshot
                  10.7.2.    Overview
                  10.7.3.    Offerings
                  10.7.4.    Financial Insight
                  10.7.5.    Recent Developments
       10.8.   Julphar Gulf Pharmaceutical Industries
                  10.8.1.    Snapshot
                  10.8.2.    Overview
                  10.8.3.    Offerings
                  10.8.4.    Financial Insight
                  10.8.5.    Recent Developments
       10.9.   Dongbao Enterprise Group Co. Ltd
                  10.9.1.    Snapshot
                  10.9.2.    Overview
                  10.9.3.    Offerings
                  10.9.4.    Financial Insight
                  10.9.5.    Recent Developments
       10.10.   Gan & Lee Pharmaceuticals Ltd.
                  10.10.1.    Snapshot
                  10.10.2.    Overview
                  10.10.3.    Offerings
                  10.10.4.    Financial Insight
                  10.10.5.    Recent Developments

11.    Appendix

         11.1.    Exchange Rates
         11.2.    Abbreviations

Note: Financial insight and recent developments of different companies are subject to the availability of information in the secondary domain.